Lilly Gains Amyvid Approval, But Reimbursement Still A Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly’s Avid has gained approval for its imaging agent Amyvid, a new tool in the Alzheimer’s disease diagnosis arsenal.
You may also be interested in...
FDA Review Of GE’s Vizamyl Shows Caution In The Face Of Alzheimer’s Disease Unknowns
Regulators approved the PET imaging agent for estimating neuritic plaque density in the brain despite the apparent limited clinical utility of the class.
Deals Of The Week: Russia Says “Nyet” To Abbott’s Buyout Of Domestic Vaccine Company
As “The Pink Sheet” team heads to BIO’s annual partnering convention in Chicago, the Russian government rejects Abbott’s bid for NGO Petrovax. Plus news on deals between Roche and Ascletis, Lilly and Siemens, and Santaris and Bristol-Myers.
Merck Inks Deal For Second Alzheimer’s Test, This Time With Luminex
Luminex will develop a companion diagnostic for Merck’s BACE Inhibitor, MK-8931, that will test patients’ cerebrospinal fluid for the presence of two biomarkers that could indicate they are at risk of developing Alzheimer’s disease.